Vorinostat does not improve outcome in patients with acute myeloid leukemia and high risk myelodysplasia treated with azacitidine: Results of the UK Trials Acceleration Programme Ravva Trial
المؤلفون الرئيسيون: | , , , , , , , , , , , , , , |
---|---|
التنسيق: | Conference item |
منشور في: |
American Society of Hematology
2016
|